Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Income from Continuing Operations across 17 years of filings, most recently posting -$3.1 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 3.54% year-over-year to -$3.1 million; the TTM figure through Jun 2026 stood at -$9.6 million (down 85.21% YoY), while the FY2025 annual figure was -$2.9 million, up 55.75% from the prior year.
• Income from Continuing Operations came in at -$3.1 million for Q2 2026 at Cumberland Pharmaceuticals, up from -$3.1 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $1.2 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
• Average Income from Continuing Operations over 5 years is -$1.7 million, with a median of -$1.5 million recorded in 2024.
• Year-over-year, Income from Continuing Operations tumbled 1204.25% in 2024 and jumped 165.61% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$2.5 million in 2022, then slumped by 156.21% to -$6.3 million in 2023, then jumped by 69.82% to -$1.9 million in 2024, then gained by 25.57% to -$1.4 million in 2025, then slumped by 119.31% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$3.1 million in Q2 2026, -$3.1 million in Q1 2026, and -$1.4 million in Q4 2025.